X0306 4 2017-10-02 0001472091 Edge Therapeutics, Inc. EDGE 0001652973 Leuthner Brian A 300 CONNELL DRIVE, SUITE 4000 BERKELEY HEIGHTS NJ 07922 1 1 President and CEO Common Stock 2017-10-02 4 S 0 2500 10.81 D 110236 D Common Stock 2017-10-03 4 S 0 2500 10.93 D 107736 D Common Stock 2017-10-04 4 S 0 2500 11.14 D 105236 D Common Stock 162000 I By Spouse Common Stock 223622 I By Trust The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.70 to $10.90 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.77 to $11.09 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $11.07 to $11.22 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. /s/ Albert N. Marchio II, attorney-in-fact 2017-10-04